OBJECTIVE: To evaluate the cost-effectiveness of Project Dulce, a culturally specific diabetes case management and self-management training program, in four cohorts defined by insurance status. DATA SOURCES/STUDY SETTING: Clinical and cost data on 3,893 persons with diabetes participating in Project Dulce were used as inputs into a diabetes simulation model. STUDY DESIGN: The Center for Outcomes Research Diabetes Model, a published, peer-reviewed and validated simulation model of diabetes, was used to evaluate life expectancy, quality-adjusted life expectancy (QALY), cumulative incidence of complications and direct medical costs over patient lifetimes (40-year time horizon) from a third-party payer perspective. Cohort characteristics, treatment effects, and case management costs were derived using a difference in difference design comparing data from the Project Dulce program to a cohort of historical controls. Long-term costs were derived from published U.S. sources. Costs and clinical benefits were discounted at 3.0 percent per annum. Sensitivity analyses were performed. PRINCIPAL FINDINGS: Incremental cost-effectiveness ratios of $10,141, $24,584, $44,941, and $69,587 per QALY gained were estimated for Project Dulce participants versus control in the uninsured, County Medical Services, Medi-Cal, and commercial insurance cohorts, respectively. CONCLUSIONS: The Project Dulce diabetes case management program was associated with cost-effective improvements in quality-adjusted life expectancy and decreased incidence of diabetes-related complications over patient lifetimes. Diabetes case management may be particularly cost effective for low-income populations.
OBJECTIVE: To evaluate the cost-effectiveness of Project Dulce, a culturally specific diabetes case management and self-management training program, in four cohorts defined by insurance status. DATA SOURCES/STUDY SETTING: Clinical and cost data on 3,893 persons with diabetes participating in Project Dulce were used as inputs into a diabetes simulation model. STUDY DESIGN: The Center for Outcomes Research Diabetes Model, a published, peer-reviewed and validated simulation model of diabetes, was used to evaluate life expectancy, quality-adjusted life expectancy (QALY), cumulative incidence of complications and direct medical costs over patient lifetimes (40-year time horizon) from a third-party payer perspective. Cohort characteristics, treatment effects, and case management costs were derived using a difference in difference design comparing data from the Project Dulce program to a cohort of historical controls. Long-term costs were derived from published U.S. sources. Costs and clinical benefits were discounted at 3.0 percent per annum. Sensitivity analyses were performed. PRINCIPAL FINDINGS: Incremental cost-effectiveness ratios of $10,141, $24,584, $44,941, and $69,587 per QALY gained were estimated for Project Dulce participants versus control in the uninsured, County Medical Services, Medi-Cal, and commercial insurance cohorts, respectively. CONCLUSIONS: The Project Dulce diabetes case management program was associated with cost-effective improvements in quality-adjusted life expectancy and decreased incidence of diabetes-related complications over patient lifetimes. Diabetes case management may be particularly cost effective for low-income populations.
Authors: Andrew J Palmer; Stéphane Roze; Morten Lammert; William J Valentine; Michael E Minshall; Lars Nicklasson; Mari-Anne Gall; Giatgen A Spinas Journal: Curr Med Res Opin Date: 2004-08 Impact factor: 2.580
Authors: Andrew J Palmer; Stéphane Roze; William J Valentine; Michael E Minshall; Volker Foos; Francesco M Lurati; Morten Lammert; Giatgen A Spinas Journal: Curr Med Res Opin Date: 2004-08 Impact factor: 2.580
Authors: Andrew J Palmer; Stéphane Roze; William J Valentine; Michael E Minshall; Volker Foos; Francesco M Lurati; Morten Lammert; Giatgen A Spinas Journal: Curr Med Res Opin Date: 2004-08 Impact factor: 2.580
Authors: K M Venkat Narayan; James P Boyle; Theodore J Thompson; Stephen W Sorensen; David F Williamson Journal: JAMA Date: 2003-10-08 Impact factor: 56.272
Authors: Athena Philis-Tsimikas; Chris Walker; Lisa Rivard; Gregory Talavera; Joachim O F Reimann; Michelle Salmon; Rachel Araujo Journal: Diabetes Care Date: 2004-01 Impact factor: 19.112
Authors: Andrew J Palmer; Stéphane Roze; William J Valentine; Giatgen A Spinas; Jonathan E Shaw; Paul Z Zimmet Journal: Clin Ther Date: 2004-02 Impact factor: 3.393
Authors: Sue Garrett; C Raina Elley; Sally B Rose; Des O'Dea; Beverley A Lawton; Anthony C Dowell Journal: Br J Gen Pract Date: 2011-03 Impact factor: 5.386
Authors: Judy Quan; Alexandra K Lee; Margaret A Handley; Neda Ratanawongsa; Urmimala Sarkar; Samuel Tseng; Dean Schillinger Journal: Popul Health Manag Date: 2015-06-23 Impact factor: 2.459
Authors: Verughese Jacob; Sajal K Chattopadhyay; David P Hopkins; Jeffrey A Reynolds; Ka Zang Xiong; Christopher D Jones; Betsy J Rodriguez; Krista K Proia; Nicolaas P Pronk; John M Clymer; Ron Z Goetzel Journal: Am J Prev Med Date: 2019-03 Impact factor: 5.043
Authors: Thomas J Flottemesch; Sarah Hudson Scholle; Patrick J O'Connor; Leif I Solberg; Steve Asche; L Gregory Pawlson Journal: Med Care Date: 2012-08 Impact factor: 2.983